Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC trimmed its position in Hologic, Inc. (NASDAQ:HOLX) by 8.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,990 shares of the medical equipment provider’s stock after selling 821 shares during the period. Fisher Asset Management LLC’s holdings in Hologic were worth $642,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of HOLX. Envestnet Portfolio Solutions Inc. purchased a new position in Hologic in the 3rd quarter valued at $903,000. LPL Financial LLC boosted its position in shares of Hologic by 12.4% during the 3rd quarter. LPL Financial LLC now owns 350,822 shares of the medical equipment provider’s stock worth $24,347,000 after purchasing an additional 38,707 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Hologic by 134.6% during the 3rd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 9,901 shares of the medical equipment provider’s stock worth $687,000 after purchasing an additional 5,680 shares in the last quarter. Trexquant Investment LP boosted its position in shares of Hologic by 114.6% during the 3rd quarter. Trexquant Investment LP now owns 172,815 shares of the medical equipment provider’s stock worth $11,993,000 after purchasing an additional 92,287 shares in the last quarter. Finally, Treasurer of the State of North Carolina boosted its position in shares of Hologic by 0.4% during the 3rd quarter. Treasurer of the State of North Carolina now owns 156,273 shares of the medical equipment provider’s stock worth $10,845,000 after purchasing an additional 554 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Up 1.2 %

Shares of HOLX stock opened at $73.07 on Monday. The firm has a 50-day moving average price of $74.59 and a 200 day moving average price of $74.20. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $82.45. The company has a market capitalization of $17.05 billion, a price-to-earnings ratio of 37.28, a PEG ratio of 2.40 and a beta of 1.00. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.05. Hologic had a net margin of 11.78% and a return on equity of 18.91%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the prior year, the company posted $1.06 EPS. The company’s quarterly revenue was down .8% compared to the same quarter last year. Research analysts forecast that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the topic of several research analyst reports. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Needham & Company LLC restated a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Friday, May 3rd. Evercore ISI boosted their price objective on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Argus boosted their price objective on shares of Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $85.60.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.